Table 1.
Patient characteristics.
| Baseline Characteristics | All Cases (n = 79) |
|---|---|
| Age (years), mean ± std | 69.5 ± 13.9 |
| Sex, n (%) | |
| Male | 41 (52) |
| Female | 38 (48) |
| Type of melanoma, n (%) * | |
| NM | 15 (19) |
| SSM | 30 (38) |
| Ocular | 4 (5) |
| ALM | 2 (3) |
| LMM | 5 (6) |
| MLM | 7 (9) |
| Unknown primitive | 7 (9) |
| Other | 9 (11) |
| Mutation status, n (%) | |
| NRAS | 31 (39) |
| BRAF | 11 (14) |
| NRAS + CKIT | 2 (3) |
| Wild | 35 (44) |
| Immunotherapy, n (%) | |
| Nivo | 63 (80) |
| Ipi + Nivo | 15 (19) |
| Pembro | 1 (1) |
| Line, n (%) | |
| 1 | 30 (38) |
| 2 | 24 (30) |
| 3 | 16 (20) |
| ≥4 | 9 (11) |
| Duration of actual immunotherapy (days), median (IQR) | 146 (85–255) |
| Previously treated by PD1i, n (%) | 29 (37) |
| Overall response rate (ORR), n (%) ** | |
| CR Complete response | 16 (25) |
| S Stability | 12 (18) |
| PR Partial response | 11 (17) |
| P Progression | 26 (40) |
* NM: nodular melanoma; SSM: Superficial Spreading Melanoma; Ocular: Ocular melanoma; ALM: Acro Lentiginous melanoma; LMM: Lentigo Malignant Melanoma; MLM: MucosalLentiginous Melanoma; Other: not classifiable (4) or not specified (4) or desmoplastic (1); ** Data missing for 14 patients.